“The present condition has exposed some structural weaknesses in the EU’s medicines offer chain along with a substantial dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides explained. She proposed that supply chain challenges be addressed within an EU pharmaceutical method predicted to get released by the tip with